Dongkook Pharmaceutical Expands Export of Popol Injection to Four Countries

Increased Demand for Sedative Effect in Severe COVID-19 Patients

[Asia Economy Reporter Choi Dae-yeol] Dongkook Pharmaceutical is expanding the countries to which it supplies Propofol injections. Following the start of exports to European regions such as the Netherlands and Luxembourg last month, it has decided to supply Singapore within this month. In September, it will also export emergency supply quantities to Japan.

Propofol injection is an injectable drug containing the active ingredient propofol, used to sedate patients in severe conditions undergoing general anesthesia or mechanical ventilation. Due to the pandemic, the number of COVID-19 patients has surged worldwide, increasing the demand for this drug.

When infected with COVID-19, respiratory symptoms may worsen as the disease progresses to pneumonia. According to the company, using Propofol injections in the treatment of severe patients helps alleviate respiratory distress and reduce pain, making it an essential medicine. Although about 80% of COVID-19 patients are mild cases, elderly patients or those with underlying conditions may worsen to severe states.

A company representative stated, "This export was made following an urgent request from the Luxembourg Embassy in Korea, and exports are ongoing with other countries as well," adding, "The export volume of Propofol injections is expected to increase significantly compared to last year."

This content was produced with the assistance of AI translation services.